{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:30:12Z","timestamp":1792251012595,"version":"4.4.0"},"reference-count":58,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,5]],"date-time":"2008-03-05T00:00:00Z","timestamp":1204675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title><jats:sc>Summary<\/jats:sc><\/jats:title><jats:p><jats:bold>Unverricht\u2010Lundborg disease (ULD), progressive myoclonic epilepsy type 1 (EPM1, OMIM254800), is an autosomal recessively inherited neurodegenerative disorder characterized by age of onset from 6 to 16 years, stimulus\u2010sensitive myoclonus, and tonic\u2013clonic epileptic seizures. Some years after the onset ataxia, incoordination, intentional tremor, and dysarthria develop. Individuals with EPM1 are mentally alert but show emotional lability, depression, and mild decline in intellectual performance over time. The diagnosis of EPM1 can be confirmed by identifying disease\u2010causing mutations in a cysteine protease inhibitor cystatin B (<jats:italic>CSTB<\/jats:italic>) gene. Symptomatic pharmacologic and rehabilitative management, including psychosocial support, are the mainstay of EPM1 patients' care. Valproic acid, the first drug of choice, diminishes myoclonus and the frequency of generalized seizures. Clonazepam and high\u2010dose piracetam are used to treat myoclonus, whereas levetiracetam seems to be effective for both myoclonus and generalized seizures. There are a number of agents that aggravate clinical course of EPM1 such as phenytoin aggravating the associated neurologic symptoms or even accelerating cerebellar degeneration. Sodium channel blockers (carbamazepine, oxcarbazepine) and GABAergic drugs (tiagabine, vigabatrin) as well as gabapentin and pregabalin may aggravate myoclonus and myoclonic seizures. EPM1 patients need lifelong clinical follow\u2010up, including evaluation of the drug\u2010treatment and comprehensive rehabilitation.<\/jats:bold><\/jats:p>","DOI":"10.1111\/j.1528-1167.2008.01546.x","type":"journal-article","created":{"date-parts":[[2008,3,5]],"date-time":"2008-03-05T22:45:08Z","timestamp":1204757108000},"page":"549-556","source":"Crossref","is-referenced-by-count":175,"title":["Clinical picture of EPM1\u2010Unverricht\u2010Lundborg disease"],"prefix":"10.1111","volume":"49","author":[{"given":"Reetta","family":"K\u00e4lvi\u00e4inen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Khyuppenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Koskenkorva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritva","family":"Vanninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Mervaala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb00482.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.11.014"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607313150506"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh377"},{"key":"e_1_2_7_6_1","first-page":"1","article-title":"Opinion: predictive testing for Huntington disease in childhood: challenges and implications","volume":"46","author":"Bloch M","year":"1990","journal-title":"Am J Hum Genet"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110193.78872.DD"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1600981"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.43703.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.9.1447"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90749-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s11.3.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.10.006"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1993.tb04105.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1112"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1990.tb00924.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1684\/j.1950-6945.2000.tb00445.x","article-title":"Antimyoclonic effect of levetiracetam","volume":"2","author":"Genton P","year":"2000","journal-title":"Epileptic Disord"},{"key":"e_1_2_7_18_1","first-page":"503","article-title":"[Unverricht\u2010L\u00fcndborg disease: clinical and electrophysiologic study of 19 Maghreb families]","volume":"154","author":"Gouider R","year":"1998","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92713-R"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.6.928"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510160042008"},{"key":"e_1_2_7_22_1","first-page":"113","article-title":"Hereditary Unverricht\u2010Lundborg myoclonus epilepsy in Congolese Negroes","volume":"34","author":"Janssen P","year":"1954","journal-title":"Ann Soc Belg Med Trop"},{"key":"e_1_2_7_23_1","article-title":"Molecular background of EPM1\u2010Unverricht\u2010Lundborg disease","author":"Joensuu T","year":"2007","journal-title":"Epilepsia"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201723"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01118.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1974.tb02782.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1974.tb02783.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.3.344"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1991.tb05549.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0397-298"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/386847a0"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1086\/301798"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2384"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00895.x"},{"key":"e_1_2_7_35_1","unstructured":"LehesjokiAE K\u00e4lvi\u00e4inenR. (2007)Unverricht\u2010Lundborg disease. In:GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright University of Washington Seattle. 1997\u20132007. Updated 18\u2010Sep\u20102007. Available athttp:\/\/www.genetests.org. Accessed [03\u2010Jan\u20102008]."},{"key":"e_1_2_7_36_1","volume-title":"Die progressive Myoclonus\u2010Epilepsie (Unverricht's Myoclonie)","author":"Lundborg H","year":"1903"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.56902.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00553.x"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1686"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1050"},{"key":"e_1_2_7_41_1","first-page":"307","article-title":"Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood","volume":"95","author":"Medina MT","year":"2005","journal-title":"Adv Neurol"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.1.53"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-002-0755-x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2003.03703.x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.1979.tb01770.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01232.x"},{"key":"e_1_2_7_47_1","first-page":"1731","volume":"271","author":"Pennacchio LA","year":"1996","journal-title":"Mutations in the gene encoding Sclence"},{"key":"e_1_2_7_48_1","first-page":"6","article-title":"Effect of high dose of oral piracetam on myoclonus in progressive myoclonus epilepsy. (Mediteranean myoclonus)","volume":"32","author":"Remy C","year":"1991","journal-title":"Epilepsia"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70043-0"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb05126.x"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.05002.x"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00293.x"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510200069016"},{"key":"e_1_2_7_54_1","first-page":"4407","article-title":"Electroencephalographic study of myoclonic cerebellar dyssynergia with epilepsy (Ramsay\u2010Hunt syndrome)","author":"Tassinari CA","year":"1974","journal-title":"Rev Electroencephalogr Neurophysiol Clin"},{"key":"e_1_2_7_55_1","unstructured":"TruongD TaiKK. (2005)Effect of Brivaracetam (ucb 34714) in a rat model of post\u2010hypoxic myoclonus. UCB code: RRLE05J1201."},{"key":"e_1_2_7_56_1","volume-title":"Die Myoclonie","author":"Unverricht H","year":"1891"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0497-393"},{"key":"e_1_2_7_58_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.33588\/rn.2902.99157","article-title":"Progressive myoclonic epilepsy: clinical characteristics of 18 patients","volume":"29","author":"Vistorte A","year":"1999","journal-title":"Rev Neurol"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.004"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2008.01546.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2008.01546.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T22:52:43Z","timestamp":1738104763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2008.01546.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,5]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1528-1167.2008.01546.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01546.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,5]]}}}